ANGLE PLC chief executive Andrew Newland talked with Proactive's Stephen Gunnion about groundbreaking new research using its Parsortix system. The study, conducted by the Marchetti lab at the University of New Mexico Comprehensive Cancer Center, uncovered key insights into how cancer spreads.
Newland explained that Parsortix, the only FDA-cleared system for recovering cancer cells for analysis, was used to study circulating tumor cell (CTC) clusters. The research found that B cells influence the movement of cancer clusters, accelerating metastasis. These findings open new avenues for understanding and potentially preventing cancer spread.
The study also suggests that detecting B cell CTC clusters in melanoma patients could help identify those at risk of disease progression. Pharmaceutical companies may explore ways to target these mechanisms to slow or stop metastasis.
Additionally, Newland highlighted a collaboration with Illumina, with ANGLE set to present at an Illumina webinar. This event could drive further adoption of Parsortix for advanced cancer research.
For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and enable notifications for future content.
#ANGLEPLC #CancerResearch #Parsortix #CTCClusters #Metastasis #Biotech #LiquidBiopsy #Illumina #MedicalBreakthrough #FDAApproved
